The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
